LeMaitre Vascular's (LMAT) steady average selling price increases for its products raised questions over its sustainability, Oppenheimer said in a Friday note.
"Continually switching to direct selling platforms helps in
tolerating ASP increases and allows for higher GM on products, though unclear how sustainable the consistent pricing increases are in the longer-term," Oppenheimer analysts said.
In addition to the sustainability issue, they also pointed to the premium valuation of the shares and potential tariff impact.
Oppenheimer downgraded the stock to perform from outperform and removed its $93 price target, saying that it is "moving to the sidelines as PT achieved."
LeMaitre shares were down more than 7% in recent trading.
Price: 92.74, Change: -7.17, Percent Change: -7.17
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。